TanJian Future Secures Tens of Millions of RMB in Series A Funding to Empower Life Science Innovation and Government Industrial Upgrading with AI

Recently, “Tanjian Future” announced the completion of its Series A financing round, raising tens of millions of RMB. This round was exclusively invested by Guanda Holding Group. The funds will be used to accelerate the construction of a digital and intelligent innovation industry service system, market expansion, and the development of a professional service team.

Tanjian Future, established in 2017 and formerly known as “Probe Capital,” a leading boutique investment bank in China’s healthcare sector, focuses on frontier innovation trends in the global biopharmaceutical and life health industries. Committed to empowering scientists and entrepreneurs driving medical progress, the company adheres to a data-driven business philosophy. Leveraging big data and artificial intelligence technologies, Tanjian Future provides diversified services—including financing and M&A, industry consulting, and operational support—to healthcare innovators, government agencies, and industrial sectors.

Wuhan Tanjian Future Technology Co., Ltd., formerly known as “Probe Capital,” is a well-known boutique investment bank in the healthcare and life sciences sector. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. Since its inception, Probe Capital has consistently completed double-digit private equity financing and M&A transactions annually, with cumulative deal values reaching tens of billions of RMB. In terms of value-added services for enterprises, the Probe Capital team also boasts extensive and mature industry experience.

According to data from “Shennong No. 1,” an industrial data platform independently developed by Wuhan Tanjian Future Technology Co., Ltd., investment and financing in China’s healthcare sector grew from over RMB 70 billion in 2017 to more than RMB 250 billion in 2021, representing an increase of nearly 350% over this five-year period. Alongside this surge in capital availability, boutique investment banks also experienced a wave of rapid growth. In 2022, shifting macroeconomic conditions combined with changes in the economic cycle led to a restructuring of market dynamics. For boutique investment banks, only by deepening their industry integration and actively engaging in operations can they fully leverage their institutional value-added capabilities.

Through deep engagement in the industry, Probe Capital has developed its unique strategic approach and operational model. In 2020, Probe Capital began establishing an industrial database for the healthcare and life sciences sectors. After several iterations, it officially launched its self-developed industrial data platform, “Shennong No. 1,” in 2022.

In terms of anchoring strategic tracks, Probe Capital has built its proprietary labeling system for the healthcare and life sciences industries, leveraging in-depth industry research and industrial data. It tracks multi-dimensional intelligence—including regulatory policies, research projects, patents, registration and certification filings, and investment and financing dynamics—across more than 900 global tracks in real time. Centered on disease spectra and industrial landscapes, and guided by technological innovation pathways, Probe Capital has established a research matrix to continuously identify high-potential tracks.

In enhancing transaction efficiency, Probe Capital has annotated nearly 100,000 innovative enterprises and approximately 20,000 investment institutions globally. Moving beyond the traditional boutique investment banking model that relies solely on network-based intelligence gathering and analysis, Probe Capital has established profiles of innovative enterprises and investment firms using quantitative metrics. This approach covers more than 3,000 active healthcare-focused investment institutions in China, effectively improving the efficiency and accuracy of financing and M&A transactions.

Yan Jingjing, Founding Partner of Probes Capital, believes that only by truly understanding the clinical and business scenarios of investment and gaining insight into the laws of technological development can one accurately navigate direction in the era of rapid iteration in life sciences, and identify high-return, high-potential “non-consensus opportunities” within the investment window of new tracks.

On the eve of the synthetic biology boom, Probe Capital completed multiple rounds of financing or M&A for companies such as Enzyme Science, Bluepha, and Diwin Biotechnology starting from 2018. In 2019, Probe Capital identified the impending explosion of the mRNA sector and decisively entered the field to serve or invest in several star companies. On the eve of the rise of digital therapeutics in China, Probe Capital published the first Chinese industry research report on digital therapeutics in 2020, and in the following years, served or invested in a number of leading enterprises in their respective niche sectors, including Zhiyun Health, Jianhai Technology, Qianglian Zhichuang, and Haixin Zhihui.

To date, Probe Capital has completed over 200 in-depth industry research reports, facilitated cumulative transaction volumes amounting to tens of billions of RMB, and consistently executed double-digit private equity financing and M&A deals annually, maintaining a transaction success rate firmly within the industry’s top tier. In 2023, IT Juzi released the “2022 China Healthcare Financial Advisory Transaction Volume Excellence List,” on which Probe Capital ranked first in the healthcare sector for 2022. Additionally, Probe Capital has garnered numerous accolades, including the “2023 Pengcheng Awards – Healthcare Financial Advisor of the Year” and a spot among the “Top 5 Best Boutique Investment Banks in the Biopharmaceutical Industry” on the “2022 China Biopharmaceutical Industry Value List.” These achievements underscore the exceptional performance of its research- and data-driven transaction model.

The current healthcare innovation landscape is evolving rapidly, with vast amounts of information fragmented across various channels. On the funding side, there are significant shifts in currency denominations and investor profiles; on the industry side, emerging trends are becoming increasingly dispersed. Relying solely on manual outreach and research makes it difficult to achieve comprehensive awareness of industry dynamics. This poses a systemic challenge for local governments and industrial parks prioritizing the development of the medical and biopharmaceutical sectors: how to obtain high-quality, reliable industry intelligence, engage and attract high-caliber innovative enterprises, and accelerate the construction and development of specific industry chains.

The digital and intelligent transformation of industrial services for the healthcare and life sciences sectors is urgently needed.

In response to these challenges, Probe Capital leverages its “Shennong No. 1” platform and data capabilities to provide local governments and industrial parks with comprehensive solutions. By utilizing multi-dimensional data, the platform rapidly identifies target industries and efficiently generates strategic investment attraction maps. Furthermore, Probe Capital’s professional investment promotion team utilizes its proprietary corporate ecosystem to systematically engage innovative enterprises through roadshows, summits, salons, and training programs. During the engagement process, multi-dimensional industry intelligence enables government agencies and industrial parks to conduct thorough benchmarking assessments, thereby optimizing the allocation of investment attraction resources and enhancing operational efficiency.

Industrial services are fundamentally underpinned by profound industry insights and a diverse network of partners. In response to the needs of regional industrial upgrading, Probe Capital has participated in or hosted more than 10 industry summits, with over 800 projects attending; undertaken or co-hosted more than 10 national mass entrepreneurship and innovation competitions, recruiting nearly 2,000 participating enterprises; and organized more than 60 specialized roadshows covering multiple sub-sectors including pharmaceuticals, medical devices, digital health, and healthcare services, with over 300 projects and enterprises participating and more than 11,000 investor attendances. Additionally, it has held or co-held nearly 30 customized training sessions, training more than 1,000 members of founding teams from innovative enterprises. Furthermore, Probe Capital maintains annual discussions and visits with over 2,000 high-potential medical innovation projects, continuously expanding its industry network.

Years of transaction and investment experience enable the Probes Capital team to proactively and comprehensively understand the needs of healthcare and life sciences innovation enterprises at different stages of development. Leveraging the power of data and platforms, the Probes team is also able to grasp the development trajectories and trends of the industrial chain and its sub-sectors. Within Probes’ ecosystem, the needs for local industrial transformation and upgrading are rapidly matched with the resource and location requirements for innovative enterprises to establish operations, quickly sparking synergistic chemical reactions.

Currently, focusing on talent acquisition and investment promotion, Wuhan Tanjian Future Technology Co., Ltd. has launched its related businesses in multiple regions including Beijing, Shanghai, Zhejiang, Jiangsu, and Sichuan, with a number of high-quality enterprises successfully partnering with regional governments or industrial parks.

From a medium- to long-term perspective, driven by population aging and rising healthcare expenditures, significant unmet clinical needs persist in the healthcare sector. The fundamental outlook for abundant opportunities in China’s healthcare market remains unchanged.

Leveraging the Shennong No. 1 Industrial Data Platform, the Probe Capital brand has been officially upgraded to “Tanjian Future.” Evolving from its origins as a boutique investment bank, it has continuously expanded its service boundaries to gradually establish a one-stop life sciences innovation industry service platform, encompassing multidimensional services such as corporate financial advisory, government industrial investment promotion and operation, and equity investment.

Regarding the securing of this round of financing,Yan Jingjing, Founding Partner of Tanjian Futurestated: “We aim to support scientists and entrepreneurs driving medical advancements, accompanying them throughout their growth journey so that they do not face existential crises due to factors beyond technology. Meanwhile, we look forward to Wuhan Tanjian Future Technology Co., Ltd.’s evolution from virtual to tangible operations, leveraging a data platform to provide diversified industrial services for all stakeholders, building a one-stop life science innovation industry service platform, and becoming the strongest enabler of innovative industries.”

Regarding this investment in Wuhan Tanjian Future Technology Co., Ltd.,Li Wei, Deputy General Manager of the Investment Department, GUANDA HOLDING GROUP“GUANDA HOLDING GROUP is currently undergoing a comprehensive digital transformation. We are also actively monitoring the transformative opportunities that digitalization and AI bring to various industries. Through long-term, in-depth tracking, we have found that Wuhan Tanjian Future Technology Co., Ltd. truly starts from business scenarios, aligns with customer needs and industrial trends, leverages data-driven investment and financing, and extends these capabilities deep into corporate business development, thereby genuinely empowering the technology industry.”

Chongqing Guanda Holding Group, formerly known as Chongqing New Century Cruise Co., Ltd.—a company listed on the SME Board of the Shenzhen Stock Exchange—was hailed as the “first IPO in Yangtze River shipping,” the “first cruise stock,” the “first tourism enterprise stock in Chongqing,” and the “first privately owned tourism enterprise stock in China.” With a thirty-year history, the Group has evolved into an international diversified enterprise integrating three major industrial clusters: high-tech-driven industrial equity investment, modern financial investment grounded in safety, responsibility, and stability, and global tourism centered on large-scale cruises and comprehensive travel services.